pulmonary hypertension, interstitial lung disease, chronic obstructive pulmonary disease
Conditions
Interventions
None listed
Sponsors
Hokkaido University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Those in whom the comprehensive consent for research use of specimens was obtained at the time of autopsy from the family member, and the following criteria were met - Patient group to be studied (Lung-PH group): Those who had been diagnosed with pulmonary hypertension associated with lung disease (Lung-PH) by examinations including right heart catheterization after January 1st, 2001 - Control group 1 (Control group): Those who died after January 1st, 2001 for reasons other than overt cardiopulmonary disease, and the histopathological specimens were stored at the Department of Pathology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University or Department of Cancer Pathology, Faculty of Medicine, Hokkaido University - Control group 2 (PH group other than Lung-PH): Those who had been diagnosed with PH other than Lung-PH by examinations including right heart catheterization and/or autopsy, and the histopathological specimens were stored at Department of Pathology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University or Department of Cancer Pathology, Faculty of Medicine, Hokkaido University - Control group 3 (Lung-NoPH group): Those who had been diagnosed with lung disease without PH (interstitial lung disease, chronic obstructive pulmonary disease, etc.) by examinations including echocardiography and/or autopsy, and the histopathological specimens were stored at Department of Pathology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University or Department of Cancer Pathology, Faculty of Medicine, Hokkaido University 2. When the voluntary consent to participate in this study has been obtained from legal representative(s) of the patients including close relative or when there has been no refusal for the participation to the present study.
Exclusion criteria
Exclusion criteria: Those who are judged by the principal investigator to be inappropriate as research subjects
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Area ratio of media and intima of pulmonary muscular arteries | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Luminal stenosis rate of pulmonary muscular arteries 2. Distribution density, wall thickening, and stenosis or dilation of pulmonary veins and lymph vessels; the presence and the degree, if present, of capillary lesions 3. Relationship between the degree of pulmonary vascular lesions and background lung lesions (emphysema, fibrosis, etc.) 4. The degree, if present, of pathological changes such as myocardial hypertrophy and fibrosis 5. Histological analysis on the target protein of pulmonary vasodilators in pulmonary blood vessels and myocardium 6. Relationship between the morphological findings and clinical course including the treatment response | — |
Countries
Japan
Contacts
Public ContactIchizo Tsujino
Hokkaido University Department of Respiratory Medicine, Faculty of Medicine
Outcome results
None listed